SARS CoV-2 COVID-19 Outbreak
ISAR has adopted the taxonomy and nomenclature just recommended by the Coronavirus Study Group (CSG) of the International Committee on Taxonomy of Viruses. The virus is now considered a sister to the SARS virus. This group of coronaviruses has been renamed as SARS-CoVs, and the previously known as 2019-nCoV is now named SARS CoV-2.
ISAR has also adopted the disease name indicated by WHO, COVID-19 (for coronavirus disease- 2019).
With the COVID-19 (Coronavirus disease 2019) outbreak progressing so quickly since it started last December, the situation has been very dynamic and the information equally fluid. New information has become available by the hour, drastically changing the potential impact of the epidemic or incrementally increasing our understanding of the outbreak and its agent. In such a dynamic scenario, information becomes too quickly outdated or superseded as to attempt to periodically summarize it or cover it all.
As a service to the community interested in antiviral research and development, ISAR News will instead publish in this page a list of curated links to sources with verified and current information; these links will be continuously updated.
ISAR members are invited to submit any links that may be of interest for their evaluation and potential addition to this page.
We publish this page in the hope that our members, and the antiviral community at large, will find it useful in their quest for a world in which viral outbreaks are no longer a constant major threat.
A collection of information about pre-clinical and clinical trial stage therapeutics, drugs being used in patients, and the current regulation meetings status landscape. In response to the urgency of the COVID-19 crisis, Biocentury is making this information available for free. To visit the portal, please follow this link
A collaborative resource to develop a host-pathogens mechanism based disease map for the pathogenesis of COVID-19. To participate, or to browse through the standardized information as it is being deposited, please follow this link
Background and general information about the SARS CoV-2 and the COVID-19 outbreak:
The role of nosocomial infection in the COVID-19 outbreak in Northern Italy and the importance of community based care- NEJM Catalyst "Innovations in Care Delivery"
China has now suffered of deaths in only the single digits for more than ten days running, whereas in the Republic of Korea the number of new cases appears to have stabilized in about 50-100 new cases per day for 19 days now, and in Italy the number of new daily cases appears to have started to decline slowly, and the cases remain largely confined to four regions in the North (Lombardia, Emilia Romagna, Veneto y Piemonte, which still have approximately 72% of all Italian cases) .
The Republic of Korea undertook an aggressive testing approach and has limited the number of new cases to one- to two-hundred and fifty per day in just sixteen days from the beginning, and nine days from the peak, of the outbreak
The Republic of Korea reports only 131 new cases on March 10, and 92% of Italian cases are still in Lombardia, Emilia Romagna, Veneto, Piemonte, Marche, and Toscana with Campania, Lazio and Liguria reporting more than a 100 cases and Friuli, 93.
Primary sources of official information:
All 2019-nCoV clinical trials registered and listed in "clinical trials.gov" (most are not yet recruiting)
China CDC epidemic tracking (updated daily)
Real time tracking of the epidemic by the Center for Systems Science and Engineering (CSSE), John Hopkins University
At the Epicenter of the Covid-19 Pandemic and Humanitarian Crises in Italy: Changing Perspectives on Preparation and Mitigation- NEJM Catalyst, a view from Italy about the potential major role of nosocomial transmission in the Italian outbreak
Care for Critically Ill Patients With COVID-19 JAMA insight
From Containment to Mitigation of COVID-19 in the US- JAMA viewpoint
COVID-19 Antiviral and Pharmacotherapy Recommendations- Nebraska Medicine
The Effect of the COVID-19 Pandemic on Clinic Operations -AMA Education hub
Coronavirus latest: has the outbreak in China peaked? - A commentary in Nature discussing the apparent peak and the possibility of a secondary peak around February 21 as a consequence of the return to work after the New Year Holiday
A commentary on the naming of the virus and the disease Science commentary
Covid-19: surge in cases in Italy and South Korea makes pandemic look more likely - A commentary in BMJ
Aggregated scientific information sites:
Pre-prints and Published papers:
COVID-19 Open Research Dataset Challenge (CORD-19) A database of publications in SARS CoV-2/COVID-19 assembled by AI
Two studies focusing on interactomes to identify potential drugs for repurposing (with the caveat that the safety in COVID-19 patients of drugs with known pharmacological activities is unknown):Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
MOLECULAR VIROLOGY, GENOMICS and EVOLUTION
Betacoronavirus Adaptation to Humans Involved Progressive Loss of Hemagglutinin-Esterase Lectin Activity -A paper from 2017 describing one potential adaptation that allowed previous betacoronaviruses to cross species barriers and infect humans
Cryo-EM structures of HKU2 and SADS-CoV spike glycoproteins and insights into coronavirus evolution- Structural analyses of the potential evolution of another coronavirus from bats to piglets
Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses -(The actual structure of the receptor binding domain has now been solved)
CLINICALEpidemiological and clinical characteristics of COVID-19 in adolescents and young adults
Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient- A small (n=3) study published in JAMA
Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019- Lymphopenia appears common
Clinical characteristics of 50404 patients with 2019-nCoV infection -A meta-analysis
Comparative study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting uncontrolled inflammation might not be the main reason of tissue injury Lymphopenia appears common
Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China-The largest description of the outbreak (>44,000 cases)
SARS-like WIV1-CoV poised for human emergence -A paper from 2016 rising the prospect of a new bat coronavirus entering the human population
OLDER UNCLASSIFIED PREPRINTS AND PUBLICATIONS
WHO increases the global risk level to "VERY HIGH" (10:24am EST February 28)
Detection of low levels of COVID-19 virus in pet dog in Hong Kong- the significance is still unclear
NIH clinical trial of remdesivir to treat COVID-19 begins - In Omaha, Nebraska
Four new countries reported COVID-19 in the last 24 h according to WHO records
Coronavirus latest: Infections surge outside China- Nature discussion of the latest infection clusters outside China with no known link to China
COVID-19: fighting panic with information (The Lancet Editorial)
Are pangolins infected with the 2019-nCoV?_Nature commentary on yet unpublished research- A link to the preprint presenting the (limited) evidence under "Pre-Prints and Published papers" below.
Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica)-Previously published research concluding that pangolins are infected with coronaviruses
Gilead Sciences has partnered with Chinese health authorities to conduct a randomized Phase III clinical trial of remdesivir against nCoV (links to the clinical trials under "Primary Sources of Information")
Coronavirus outbreak: what’s next? _Nature magazine commentary
Mining coronavirus genomes for clues to the outbreak’s origins Science magazine commentary
The World Health Organization (WHO) and the World Economic Forum have set up a public private collaboration to provide a platform for data sharing and operational coordination, “The Pandemic Supply Chain Network (PSCN).
About ISAR NEWS
The official newsletter of the International Society for Antiviral Research
© Publications workgroup (Communications & Outreach Committee) and Luis M Schang, Editor